LHLevon Halabelian

Levon Halabelian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Levon Halabelian has a total of 736 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Critical Assessments of Computational Hit-finding Experiments Challenge #4: Targeting the Tyrosine Kinase Binding Domain of the E3 Ligase Casitas B-Lineage Lymphoma Proto-Oncogene B, an Immuno-Oncology Target

    by Madhushika Silva, Oleksandra Herasymenko, Abd Al-Aziz A. Abu-Saleh, Suzanne Ackloo, Rima Al-Awar, Cheryl H. Arrowsmith, Ryota Ashizawa, David J. Bearss, Hartmut Beck, Kevin P. Bishop, et al.

    The critical assessments of computational hit-finding experiments (CACHE) are prospective benchmarking exercises where small molecule ligands predicted for a nominated protein of interest are procured and tested experimentally. In CACHE #4, 23 participating teams each selected up to 100 compounds designed to bind the E3 ligase CBLB, an immuno-oncology target. The organizers released the first public structure of CBLB in complex with a known ligand at the outset of the challenge to enable the discovery of chemically novel molecules. Out of the 1688 compounds collectively predicted, ten compounds from nine participants showed some sign of activity (primary hits), but only two were convincingly confirmed (validated hits) across multiple biophysical binding assays and in subsequent analogs, and only one of them was chemically novel. The apparent difficulty of finding novel CBLB ligands, previously reflected by the chemical similarity of inhibitors from the patent literature, suggests that potent CBLB hit molecules were either rare in the screened commercial libraries, or that computational methods may have struggled to retrieve presumably present but weak ligands, or that the conformational dynamics of the binding site was not sufficiently accounted for. The successful method was strikingly atypical. Selection from a chemical binding similarity classifier followed by a random forest binding affinity predictor trained on inhibitors from the patent literature was refined using a diffusion-model binding pose predictor. The road to an ML-driven breakthrough in computational hit-finding can take unexpected turns. Which of these turns reveal novel horizons and which are mere distractions will best be investigated and answered collectively. The discovery in CACHE #4 of a novel series of CBLB ligands is not a trivial achievement and may inform medicinal chemistry efforts toward clinical candidates that complement immune checkpoint inhibition to elicit antitumor immune response in cancer patients.

  • Open Access

    An Atlas of Short Linear Motif-Mediated Human Protein-Protein Interactions

    by Priyanka Madhu, Caroline Benz, Leandro Simonetti, Matthew J. Winters, Mythili S. Subbanna, Johanna Kliche, Lidia Gomez-Lucas, Hazem M Kotb, Izabella Krystkowiak, Dmitri Segal, et al.

    Short linear motifs (SLiMs) within intrinsically disordered protein regions mediate transient interactions crucial for cell physiology 1 . However, the global interaction landscape of human SLiMs remains largely uncharted. Here we present the Atlas of SLiM-mediated Human protein-protein Interactions (ASHI), which maps more than 20,000 interactions by screening over 800 human protein domains against a library of one million peptides tiling the human disordered proteome. ASHI expands the SLiM interactome, uncovers novel binding modes for known peptide-binding domains, and reveals unexpected peptide-binding activities in enzymes, chaperones, RNA-binding proteins, and modification-reader domains. Furthermore, intrinsically disordered regions emerge as densely encoded interaction platforms where interaction specificity is governed by diverse mechanisms, including key motif determinants, flanking residues, competition, and multivalency. These data provide an unprecedented foundation for modeling dynamic interaction networks, interpreting disease-associated variants, and decoding the dark proteome.


  • Open Access

    High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compounds

    by Diwen Yang, Xiaoyun Wang, Jiabao Liu, Yufeng Gong, Pranav Nair, Jianxian Sun, Xing Qian, Jingyuan Cui, Hong Zeng, Aiping Dong, et al.

    Chemical pollution is a global threat to human health, yet the toxicity mechanisms of most contaminants remains unknown. Here, we applied an ultrahigh-throughput affinity selection–mass spectrometry (AS–MS) platform to systematically identify protein targets of prioritized chemical contaminants. After benchmarking the platform, we screened 50 human proteins against 481 prioritized chemicals, including 446 ToxCast chemicals and 35 per- and polyfluoroalkyl substances (PFAS). Among 24,050 interactions assessed, we discovered 35 interactions involving 13 proteins, with fatty acid–binding proteins (FABPs) emerging as the most ligandable protein family. Given this, we selected FABPs for further validation, which revealed a distinct PFAS binding pattern: legacy PFAS selectively bound to FABP1, whereas replacement compounds, perfluoroether carboxylic acids, unexpectedly interacted with all FABPs. X-ray crystallography further revealed that the ether group enhances the molecular flexibility of alternative PFAS to accommodate the binding pockets of FABPs. Our findings demonstrate that AS–MS is a robust platform for the discovery of protein targets beyond the scope of ToxCast and highlight the broader protein-binding spectrum of alternative PFAS as potential regrettable substitutes.


  • Open Access

    Enantioselective protein affinity selection mass spectrometry (E-ASMS)

    by Xiaoyun Wang, Jianxian Sun, Shabbir Ahmad, Diwen Yang, Fengling Li, U. Hang Chan, Hong Zeng, Conrad V. Simoben, Stuart R. Green, Madhushika Silva, et al.

    We report an enantioselective protein affinity selection mass spectrometry screening approach (E-ASMS) that enables the detection of weak binders, informs on selectivity, and generates orthogonal confirmation of binding. After method development with control proteins, we screen 31 human proteins against a designed library of 8,217 chiral compounds. We identify 16 binders to 12 targets, including many proteins predicted to be “challenging to ligand”, and confirm their interactions through orthogonal biophysical assays. Seven binders to six targets display enantioselective binding, with KD values ranging from 3 to 20 µM. Binders for four targets (DDB1, WDR91, WDR55, and HAT1) are selected for in-depth characterization using X-ray crystallography. In all four cases, the mechanisms underlying enantioselectivity are readily explained. These results demonstrate that E-ASMS enables the identification and characterization of selective and weakly binding ligands for novel protein targets with unprecedented throughput and sensitivity.


  • Open Access

    Identification and Characterization of a Small Molecule Ligand for the Huntingtin-HAP40 Complex

    by Rocher Leung, Esther Wolf, Justin C. Deme, Swati Balakrishnan, Conrad V. Simoben, Shulu Feng, Jonathan D. Macdonald, Renu Chandrasekaran, Jianxian Sun, Xiaoyun Wang, et al.

    Huntington’s disease (HD) is caused by a CAG repeat expansion mutation, giving rise to a polyglutamine expansion in the huntingtin (HTT). However, the explicit molecular functions of HTT and opportunities for direct pharmacological modulation remain incompletely understood. Here, we report the discovery of a small molecule ligand for the full-length HTT protein in complex with its partner, HAP40. Using affinity selection mass spectrometry (AS-MS), we identified a stereoselective binder, whose binding was characterized by surface plasmon resonance, hydrogen-deuterium exchange mass spectrometry, and cryo-electron microscopy at 2.3 Å resolution. The ligand binds HTT-HAP40 in vitro with single-digit micromolar affinity and one-to-one stoichiometry at a druggable interface previously predicted computationally. In silico studies predicted and experimental analyses confirmed the (R)-enantiomer as the eutomer and initial structure activity relationship was established experimentally. This work details a structurally-validated chemical scaffold and highlights a ligandable pocket which could enable development of chemical probes for probing HTT biology, as well as therapeutics such as degraders and imaging agents for HD.


  • Open Access

    Enabling Open Machine Learning of Deoxyribonucleic Acid-Encoded Library Selections to Accelerate the Discovery of Small Molecule Protein Binders

    by James Wellnitz, Shabbir Ahmad, Nabin Bagale, Xuemin Cheng, Jermiah Joseph, Hong Zeng, Albina Bolotokova, Aiping Dong, Shaghayegh Reza, Pegah Ghiabi, et al.

    Machine learning (ML) is increasingly used in DNA-encoded library (DEL) screening for ligand discovery, but its success depends on access to suitable data sets, which are often proprietary and costly. To overcome this, we present the first fully open, automated DEL-ML framework using public DEL data sets and chemical fingerprints to enable reproducible, accessible drug discovery. Our workflow─from model training to virtual screening and compound selection─requires no human intervention. As a proof of concept, we identified binders for WDR91 by training ML models on the HitGen OpenDEL library (3B molecules) and screening the Enamine REAL Space library (37B molecules), yielding 50 candidates. Experimental testing confirmed seven novel binders with dissociation constants between 2.7–21 μM. Our open-source approach matches the performance of proprietary methods, demonstrating that public DEL data can support robust ML-driven ligand discovery and fostering transparency and broader community participation in drug development.


  • Open Access

    OICR-41103 as a chemical probe for the DCAF1 WD40 domain

    by Serah W. Kimani, Mahmoud Noureldin, Brian Wilson, Laurent Hoffer, Stuart R. Green, Magdalena M. Szewczyk, Héctor González-ÁlVarez, Mohammed Mohammed, Manuel Chan, Chiara Krausser, et al.

    Human DCAF1 is a multidomain protein that plays a critical role in protein homeostasis. Its WDR domain functions as a substrate recruitment module for RING-type CRL4 and HECT family EDVP E3 ubiquitin ligases, enabling the ubiquitination and proteasomal degradation of specific substrates. DCAF1’s activity has been implicated in cell proliferation and is documented to promote tumorigenesis. Additionally, the DCAF1 WDR domain is hijacked by lentiviral accessory proteins to induce the degradation of host antiviral factors, such as SAMHD1 and UNG2. These diverse roles make DCAF1 an attractive target for therapeutic development in oncology and antiviral strategies. It is also a promising candidate for use in targeted protein degradation. We previously reported a novel ligand, OICR-8268, that targets the DCAF1 WDR domain. In this study, we present the development of OICR-41103, a potent, selective, and cell-active small molecule chemical probe for DCAF1, derived from OICR-8268. The co-crystal structure of the DCAF1-OICR-41103 complex reveals the ligand’s binding mode within the WDR central pocket, demonstrating its potential for PROTAC design and development. Notably, OICR-41103 effectively displaces the lentiviral Vpr protein from DCAF1 in both biochemical and cellular settings, highlighting its potential for the development of HIV therapeutics.


  • Open Access

    Enantioselective Chemical Probe for Chikungunya nsP2 Helicase with Antialphaviral Activity

    by Bose Muthu Ramalingam, Hans J. Oh, John D. Sears, Chun-Hsing Chen, Anand Vala, Shubin Liu, Kacey M. Talbot, Mohammed Anwar Hossain, Peter J. Brown, Scott Houliston, et al.

    Chikungunya virus (CHIKV) replication relies on the multifunctional nsP2 protein, making it an attractive target for antiviral drug discovery. Here, we report the resolution of oxaspiropiperidine 1, a first-in-class inhibitor of the CHIKV nsP2 RNA helicase (nsP2hel), into its constitutive enantiomers and characterization of their antiviral activity. The enantiomer (R)-1 exhibited potent inhibition of viral replication, nsP2hel ATPase activity, and dsRNA unwinding, while the (S)-1 enantiomer was >100-fold less active. The (R)-1 enantiomer also demonstrated a high selectivity for CHIKV over other RNA viruses and for nsP2hel over other RNA helicases. Direct binding of (R)-1 to the nsP2hel protein was confirmed by 19F NMR. Biophysical and structural studies revealed conformational polymorphism in the spirocyclic scaffold of (R)-1, suggesting a potential role of thermal mobility of the ligand in allosteric inhibition of nsP2hel. Collectively, these findings designate (R)-1 (RA-NSP2-1) as a high-quality chemical probe and (S)-1 (RA-NSP2-1N) as a negative control for probing the biology of alphavirus RNA helicases.


  • Open Access

    Discovery of an exquisitely selective WDR5 chemical probe accelerated by a high-quality DEL–ML Hit

    by Lasse Hoffmann, Christopher Lenz, Frederic Farges, Serah W. Kimani, Johannes Dopfer, Sabrina Keller, Martin Peter Schwalm, Hanna Holzmann, Andreas Kraemer, Aiping Dong, et al.

    Herein we present the rapid development of LH168, a potent and highly selective chemical probe for WDR5, streamlined by utilizing a DEL–ML (DNA encoded library–machine learning) hit as the chemical starting point. LH168 was comprehensively characterized in bioassays and demonstrated potent in cellulo target engagement at the WIN-site pocket of WDR5, with an EC50 of approximately 10 nM, a long residence time, and exceptional proteome-wide selectivity for WDR5. In addition, we present the X-ray co-crystal structure and provide insights into the structure–activity relationships (SAR). In parallel, we developed a matched negative control compound as well as an alkyne analog (compound 16) to facilitate the development of bifunctional molecules. Taken together, we provide the scientific community with a well-characterized chemical probe to enable studies and functional manipulation of WDR5 in a cellular context, as this protein represents a therapeutically relevant target with scaffolding functions that influence multiple cellular processes.


  • Open Access

    Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity

    by Bose Muthu Ramalingam, John D. Sears, Kacey M. Talbot, Yuan-Wei Norman Su, Scott Houliston, Mohammed Anwar Hossain, Zachary W. Davis-Gilbert, Chunqing Zhao, Hans J. Oh, Peter J. Brown, et al.

    Alphaviruses are mosquito-borne RNA viruses that pose a significant public health threat, with no FDA-approved antiviral therapeutics available. The nonstructural protein 2 helicase (nsP2hel) is an enzyme involved in unwinding dsRNA essential for alphavirus replication. This study reports the discovery and optimization of first-in-class oxaspiropiperidine inhibitors targeting nsP2hel. Structure-activity relationship (SAR) studies identified potent cyclic sulfonamide analogs with nanomolar antiviral activity against chikungunya virus (CHIKV). Biochemical analyses of nsP2hel ATPase and RNA unwindase activities showed these compounds act in a noncompetitive mode, suggesting that they are allosteric inhibitors. Viral resistance mutations mapped to nsP2hel and a fluorine-labeled analog exhibited direct binding to the protein by 19F NMR. The lead inhibitor, 2o, demonstrated broad-spectrum antialphaviral activity, reducing titers of CHIKV, Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV). These findings support nsP2hel as a viable target for the development of broad-spectrum, direct-acting antialphaviral drugs.